Cargando…

Direct All-Cause Health Care Costs Associated With Chronic Kidney Disease in Patients With Diabetes and Hypertension: A Managed Care Perspective

BACKGROUND: Diabetes and hypertension are the 2 major causes of endstage renal disease. The rate of chronic kidney disease (CKD) secondary to diabetes and/or hypertension is on the rise, and the related health care costs represent a significant economic burden. OBJECTIVES: To quantify from a health...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laliberte, Francois, Bookhart, Brahim K., Vekeman, Francis, Corral, Mitra, Duh, Mei Sheng, Bailey, Robert A., Piech, Catherine Tak, Lefebvre, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437749/ https://www.ncbi.nlm.nih.gov/pubmed/19422271 http://dx.doi.org/10.18553/jmcp.2009.15.4.312

Ejemplares similares

All-Cause and Potentially Disease-Related Health Care Costs Associated with Venous Thromboembolism in Commercial, Medicare, and Medicaid Beneficiaries
por: Lefebvre, Patrick, et al.
Publicado: (2012)

Impact of Once-Daily Versus Twice-Daily Dosing Frequency on Adherence to Chronic Medications among Patients with Venous Thromboembolism
por: Laliberté, François, et al.
Publicado: (2013)

Unintended Consequences of Increased Out-of-Pocket Costs During Medicare Coverage Gap on Anticoagulant Discontinuation and Stroke
por: Salam, Tabassum, et al.
Publicado: (2023)

Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population
por: Berger, Jeffrey S., et al.
Publicado: (2023)

Medicaid spending on contraceptive coverage and pregnancy-related care
por: Laliberté, François, et al.
Publicado: (2014)

Venous thromboembolism recurrence among one-and-done direct oral anticoagulant users: a retrospective longitudinal study
por: Alberts, Mark, et al.
Publicado: (2023)

Ischemic Stroke and Systemic Embolism Among One-and-Done Direct Oral Anticoagulant Users with Non-valvular Atrial Fibrillation
por: Alberts, Mark, et al.
Publicado: (2023)

Novel Type 2 Diabetes Medication Access and Effect of Patient Cost Sharing
por: Henk, Henry J., et al.
Publicado: (2018)

Real‐World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B‐Cell Lymphoma in the U.S
por: Yang, Xiaoqin, et al.
Publicado: (2021)

Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data
por: Young, James B., et al.
Publicado: (2018)

Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study
por: Zilberberg, Marya D, et al.
Publicado: (2007)

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes
por: Weir, Matthew R., et al.
Publicado: (2021)

Venous Thromboembolism Recurrence Among Patients Who Abandon Oral Anticoagulant Therapy in the USA: A Retrospective Longitudinal Study
por: Alberts, Mark, et al.
Publicado: (2023)

Reduce Acute Care Costs, and All Other Healthcare Costs Too
por: Weintraub, William S.
Publicado: (2019)

Direct costs of both inpatient and outpatient care for all type cancers: The evidence from Beijing, China
por: Yin, Xuejun, et al.
Publicado: (2019)

Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis
por: Lafeuille, Marie-Hélène, et al.
Publicado: (2013)

Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population
por: Law, Amy, et al.
Publicado: (2016)

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions
por: Margolis, Jay M., et al.
Publicado: (2016)

Patient costs of hypertension care in public health care facilities in Kenya
por: Oyando, Robinson, et al.
Publicado: (2019)

Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens
por: Priest, Julie, et al.
Publicado: (2023)

Direct Costs of Hypertension Treatment in Iran
por: Zamandi, Mahmoud, et al.
Publicado: (2023)

Hypertension and Chronic Kidney Disease in Primary Care
por: Alexander, Alice
Publicado: (2016)

The Cost of Care for People With Chronic Kidney Disease
por: Manns, Braden, et al.
Publicado: (2019)

Cost-effectiveness of pharmacist care for managing hypertension in Canada
por: Marra, Carlo, et al.
Publicado: (2017)

Can social media data lead to earlier detection of drug‐related adverse events?
por: Duh, Mei Sheng, et al.
Publicado: (2016)

Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus
por: Zonnenberg, Bernard A., et al.
Publicado: (2018)

Effects of variations in access to care for children with atopic dermatitis
por: Siegfried, Elaine C., et al.
Publicado: (2020)

Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis
por: Thomasius, Friederike, et al.
Publicado: (2021)

Direct costs of rheumatoid arthritis multidisciplinary care in Ireland
por: Priyadarshini, A, et al.
Publicado: (2023)

Health-care costs of losartan and candesartan in the primary treatment of hypertension
por: Henriksson, M, et al.
Publicado: (2011)

The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States
por: Ogbomo, Adesuwa, et al.
Publicado: (2022)

Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study
por: Slade, David, et al.
Publicado: (2021)

Disease-Related and All-Cause Health Care Costs of Elderly Patients With Gout
por: Wu, Eric Q., et al.
Publicado: (2008)

Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States
por: Berger, Jeffrey S., et al.
Publicado: (2022)

Real-World Treatment Patterns and Switching Following Moderate/Severe Chronic Obstructive Pulmonary Disease Exacerbation in Patients with Commercial or Medicare Insurance in the United States
por: Bogart, Michael, et al.
Publicado: (2023)

Determinants of Direct Costs of HIV-1 Outpatient Care in Israel
por: Rom, Tom, et al.
Publicado: (2022)

A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy
por: Mapel, Douglas, et al.
Publicado: (2017)

Heartburn in Consumer-Directed Health Care and the Cost Outcomes of Therapeutic Maximum Allowable Cost
por: Curtiss, Frederic R.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_0a1kb7kq6t5t79f1mi169pbpmr